

LIST OF FIGURES

FIGURE NO.	FIGURE TITLE	PAGE NO
Figure 2.1	The p53 pathway	19
Figure 2.2	Normal p53 pathway and its function in preventing cancer	20
Figure 2.3	Diagrammatic representation of a liposome in which the bilayers of polar phospholipids alternate with aqueous compartments	28
Figure 2.4	Types of liposomes A) Conventional Liposomes B) Cationic liposomes for DNA delivery by complexation C) Stealth liposomes for intravenous delivery for prolonged circulation and D) Targeted liposomes for active targeting to a particular group of cells.	29
Figure 2.5	Dehydration-Rehydration method for liposome formation with superior entrapment	30
Figure 2.6	Supercritical Antisolvent Technique for Particle Formation	32
Figure 2.7	Schematic Representation of Cationic Lipid-DNA (Lipoplex) formation.	33
Figure 2.8	Multiple drug resistant tumor cells demonstrating poor drug action because of Pump and nonpump resistance their by enhancing the tumorigenesis.	35
Figure 2.9	p53 Plasmid Map	36
Figure 2.10	β -galactosidase Map	37
Figure 3.1	Calibration curve of plasmid DNA in Tris buffer pH 8.0	52
Figure 3.2	Hydrolysis of ONPG (colorless) to O-Nitrophenol (Yellow color) and galactose.	53
Figure 3.3	Calibration curve of β galactosidase by reacting known quantity of β gal (μ) with ONPG after 5 minutes	54
Figure 3.4	Calibration curve of β galactosidase by reacting known quantity of β gal (μ) with ONPG after 20 minutes	55

Figure 3.5	Calibration Curve of Etoposide in Methanol at 284 nm.	56
Figure 3.6	Calibration Curve of Docetaxel in Methanol at 229 nm.	57
Figure 4.1	Digestion of p53 (4A) and β gal (4B) by EcoRI and Bam HI restriction endonuclease enzyme.	71
Figure 5.1	Morphology of the nanosized extruded liposomes as studied by CryoTEM (Fig 5(a)) and of the hydrated multi-lamellar liposomes prepared by Thin Film Hydration Technique by phase contrast microscopy (Fig 5(b))	79
Figure 5.2	CryoTEM image of liposomes formed by Ethanol Injection method	80
Figure 5.3	CryoTEM study of liposomes prepared by SCF technique	83
Figure 5.4	(A) Agarose gel retardation of Plasmid alone and after complexation with liposomes at different N / P ratios prepared by TFH method	87
Figure 5.4	(B) Agarose gel retardation of Plasmid alone and after complexation with liposomes at different N / P ratios prepared by SCF method	88
Figure 5.4	(C) Agarose gel retardation of Plasmid alone and after complexation with liposomes at different N / P ratios prepared by EI method	88
Figure 5.5	Intracellular uptake of 6-coumarin lipoplexes prepared by TFH, EI and SCF techniques in H 1299	91
Figure 5.6	Intracellular uptake of 6-coumarin lipoplexes prepared by EI after Tf attachment in H 1299 cell line	97
Figure 6.1	CryoTEM studies of Etoposide and Docetaxel Liposomes showing unilamellar liposomes. (A – Etoposide, B – Docetaxel)	118
Figure 6.2	Size and zeta potential of Blank, ETP and DTX loaded lipoplexes (n=3)	122
Figure 6.3	Comparative % drug release of A) ETP liposomes and lipoplexes and B) DTX liposomes and lipoplexes in pH 7.4 PBS	123

	buffer and pH 5.4 Acetate buffer (n=3)	
Figure 6.4	Agarose gel retardation of Plasmid alone and after complexation with liposomes at different N / P ratios	125
Figure 6.5	Quantitative analysis of cellular uptake of 6-coumarin performed in H 1299 (6.5 a) and A 549 (6.5b) cell lines by flow cytometer	128
Figure 6.6	Intracellular uptake of 6-coumarin in H 1299 and A 549 Cell line	129
Figure 6.7	Transfection of β -gal pDNA after complexing with cationic liposomes at different N/P ratios in H 1299 and A 549 cell line (n=3)	132
Figure 6.8	Effect of cytotoxic chemotherapeutic agents on transfection of β -gal pDNA in H 1299 (8 A) and A 549 (8 B) cell lines.	133
Figure 6.9	Cytotoxicity of p53 and ETP / DTX formulations in H 1299 and A-549 cell lines after pre-treatment and co-administration approach	138
Figure 6.10	Percentage cells expressing p53 after transfection in H 1299 cell line.	143
Figure 6.11	FACS histograms showing shift in the fluorescence positive p53 expressing cells after transfection in H 1299 cells	143
Figure 6.12 A	Annexin V FITC dot plots for determining cell Apoptosis and Necrosis in H 1299 cell line	147
Fig 6.12 B	Annexin V FITC dot plots for determining cell Apoptosis and Necrosis in A 549 cell line	148
Figure 6.13	Graphical representation of p53 pretreatment and co-delivery with ETP and DTX for chemo-sensitization and enhanced synergistic cytotoxicity	149